ReviewInternational reviews of immunology2012
T-cell-independent antitumor effects of CD40 ligation.
Review in International reviews of immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Ponatinib Averts αCD40 Antibody Mediated Toxicity by Lowering MAPK38 Expression and Shows Proimmunogenic Effects in a Murine Tumor Model.ACS pharmacology & translational science · 2025Article
- Genetic evidence from Mendelian randomization links CD40 levels to increased risk of estrogen receptor-positive breast cancer.Scientific reports · 2025Article
- Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.Neoplasia (New York, N.Y.) · 2024Article
- Review
- Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.Frontiers in endocrinology · 2023Article
- Gestationally dependent immune organization at the maternal-fetal interface.Cell reports · 2022Article
- Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer.Cancers · 2022Article
- Article
- Review
- Agonistic CD40 Antibodies in Cancer Treatment.Cancers · 2021Review
- Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.Frontiers in immunology · 2021Review
- Article
- "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.Frontiers in immunology · 2020Review
- Novel Targets for the Treatment of Melanoma.Current oncology reports · 2019Review
- In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2019Article
- The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma.Frontiers in immunology · 2019Review
- Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.The Journal of experimental medicine · 2018Article
- Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- A Role for CD154, the CD40 Ligand, in Granulomatous Inflammation.Mediators of inflammation · 2017Article
- Deploying myeloid cells against myeloma.Oncoimmunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
CD40 ligation has been shown to induce antitumor effects in mice and cancer patients. Most of the studies have focused on the ability of an agonistic anti-CD40 mAb to either directly kill CD40-positive tumor cells or activate T-cell immune responses. In this review the authors focus on the ability of CD40 ligation to activate antitumor effector mechanisms of the cells of innate immunity such as macrophages and NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.